Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults

Figures & data

Table 1 HP/TAZ Summary Table

	Indication	Mechanism of Action	Dose	Duration of Use	Limitations of Use and Special Considerations
Halobetasol propionate (HP) and tazarotene (TAZ) combination lotion 0.01%/0.045%	Topical treatment of plaque psoriasis in adults	Anti-inflammatory and inhibition of keratinocyte hyperproliferation	Limit maximum dose to 50 g per week	Limit maximum consecutive use to 14 days	Contraindicated in pregnancy. TAZ increases risk of photosensitivity. Cannot be used for facial, axillary, or genital psoriasis

Figure 1 Achievement of primary efficacy endpoint in study 1 (NCT02462070) and study 2 (NCT02462122).^23–25

Safety and efficacy of IDP-118 in the treatment of plaque psoriasis - full text view - clinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02462070. Accessed 311, 2020..

 Google Scholar

Gold LS, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 Phase 3 randomized controlled trials. J Am Acad Dermatol. 2018;79(2):287–293. doi:10.1016/j.jaad.2018.03.04029614243

 PubMed Web of Science ®Google Scholar